• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Eli Lilly, Livent, Super Micro Computer And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

    5/3/23 6:49:51 AM ET
    $IMGN
    $LANV
    $LLY
    $LTHM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Apparel
    Consumer Discretionary
    Get the next $IMGN alert in real time by email

    U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

    • ImmunoGen, Inc. (NASDAQ:IMGN) gained 18.6% to $6.17 in pre-market trading. ImmunoGen recently announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
    • Livent Corporation (NYSE:LTHM) rose 9.2% to $22.95 in pre-market trading after the company reported better-than-expected financial results and raised its full-year 2023 guidance.
    • Lanvin Group Holdings Limited (NYSE:LANV) gained 8.9% to $5.36 in pre-market trading. Lanvin Group recently posted FY22 revenue of €422 million.
    • Eli Lilly and Company (NYSE:LLY) surged 8.8% to $439.80 in pre-market trading after the company’s Phase 3 Donanemab trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) rose 8.5% to $113.27 in pre-market trading. Super Micro Computer posted downbeat quarterly results, but issued strong forecast for the current quarter.
    • Pearson plc (NYSE:PSO) climbed 8.4% to $10.15 in pre-market trading after dropping around 15% on Tuesday.
    • Nikola Corporation (NASDAQ:NKLA) gained 5.5% to $0.9069 in pre-market trading. Nikola and decarbonization infrastructure provider Voltera signed a definitive agreement to develop the hydrogen fueling infrastructure to support Nikola's deployment of zero-emissions vehicles.
    • TORM plc (NASDAQ:TRMD) gained 5.1% to $30.35 in pre-market trading.
    • Standard Lithium Ltd. (NYSE:SLI) dropped 3.7% to $3.37 in pre-market trading following Q1 results.

    Now Read This: Qualcomm Likely To Report Lower Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Don’t forget to check out our premarket coverage here

    Get the next $IMGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMGN
    $LANV
    $LLY
    $LTHM

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Pearson Plc
    $PSO
    1/23/2026Reduce → Hold
    Kepler
    Super Micro Computer Inc.
    $SMCI
    1/13/2026$26.00Sell
    Goldman
    Pearson Plc
    $PSO
    1/12/2026Buy
    Citigroup
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    More analyst ratings

    $IMGN
    $LANV
    $LLY
    $LTHM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 26, 2024 - FDA Roundup: March 26, 2024

    For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

    3/26/24 3:38:14 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMGN
    $LANV
    $LLY
    $LTHM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liaw Yih-Shyan Wally converted options into 3,400 shares and covered exercise/tax liability with 1,220 shares, increasing direct ownership by 2% to 94,492 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:27:31 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    SVP, Chief Accounting Officer Cheung Kenneth converted options into 2,250 shares and covered exercise/tax liability with 927 shares, increasing direct ownership by 2% to 58,530 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:26:52 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Director Liu Liang Chiu-Chu Sara converted options into 3,650 shares and covered exercise/tax liability with 2,108 shares, increasing direct ownership by 0.25% to 609,800 units (SEC Form 4)

    4 - Super Micro Computer, Inc. (0001375365) (Issuer)

    2/19/26 4:26:04 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    $IMGN
    $LANV
    $LLY
    $LTHM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pearson Plc upgraded by Kepler

    Kepler upgraded Pearson Plc from Reduce to Hold

    1/23/26 8:10:44 AM ET
    $PSO
    Books
    Consumer Discretionary

    Goldman resumed coverage on Super Micro Computer with a new price target

    Goldman resumed coverage of Super Micro Computer with a rating of Sell and set a new price target of $26.00

    1/13/26 9:18:14 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    $IMGN
    $LANV
    $LLY
    $LTHM
    SEC Filings

    View All

    SEC Form 6-K filed by Pearson Plc

    6-K - PEARSON PLC (0000938323) (Filer)

    2/17/26 8:27:42 AM ET
    $PSO
    Books
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Standard Lithium Ltd.

    SCHEDULE 13G - STANDARD LITHIUM LTD. (0001537137) (Subject)

    2/13/26 9:29:46 AM ET
    $SLI
    Major Chemicals
    Industrials

    SEC Form 10-K filed by Eli Lilly and Company

    10-K - ELI LILLY & Co (0000059478) (Filer)

    2/12/26 1:58:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMGN
    $LANV
    $LLY
    $LTHM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMGN
    $LANV
    $LLY
    $LTHM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

    Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years  Additional new data revealed exceptionally low surgery and hospitalization rates in Omvoh-treated patients across both Crohn's disease and ulcerative colitis (UC), underscoring its potential to fundamentally change disease trajectory Omvoh now stands alone as the only IL-23p19 inhibitor to show strong and durable efficacy with simple, consistent monthly dosing over four years in UC and three years in Crohn's diseaseINDIANAPOLIS, Feb. 19, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE:LLY) showed Omvoh (mirikizuma

    2/19/26 12:15:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMGN
    $LANV
    $LLY
    $LTHM
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TORM plc appoints Simon Mackenzie Smith as Chair of the Board

    INSIDE INFORMATION HELLERUP, Denmark, Dec. 16, 2025 /PRNewswire/ -- TORM plc (NASDAQ:TRMD) is pleased to announce that the Board of Directors has appointed Simon Mackenzie Smith as the new Chair of the Board, succeeding Chris Boehringer. The appointment follows a planned process and reflects the Board's strong focus on ensuring continuity and long-term value creation for TORM and our shareholders. Chris Boehringer was appointed Chair of the Board in 2015 and will continue to serve as a member of the Board. During this period, TORM has strengthened our financial position and continued to develop the One TORM platform, which has been fundamental to our continued market-leading performance. "I

    12/16/25 11:31:00 AM ET
    $TRMD
    Marine Transportation
    Consumer Discretionary

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMGN
    $LANV
    $LLY
    $LTHM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Super Micro Computer Inc.

    SC 13G - Super Micro Computer, Inc. (0001375365) (Subject)

    11/14/24 12:52:53 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Amendment: SEC Form SC 13G/A filed by Nikola Corporation

    SC 13G/A - Nikola Corp (0001731289) (Subject)

    11/12/24 5:01:31 PM ET
    $NKLA
    Auto Manufacturing
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Nikola Corporation

    SC 13G/A - Nikola Corp (0001731289) (Subject)

    11/4/24 10:24:12 AM ET
    $NKLA
    Auto Manufacturing
    Consumer Discretionary

    $IMGN
    $LANV
    $LLY
    $LTHM
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supermicro Announces Second Quarter Fiscal Year 2026 Financial Results

    Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company"), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, today announced unaudited financial results for its second quarter of fiscal year 2026 ended December 31, 2025. Second Quarter Fiscal Year 2026 Highlights Net sales of $12.7 billion versus $5.0 billion in Q1'26 and $5.7 billion in Q2'25 Gross margin of 6.3% versus 9.3% in Q1'26 and 11.8% in Q2'25 Net income of $401 million versus $168 million in Q1'26 and $321 million in Q2'25 Diluted net income per common share of $0.60 versus $0.26 in Q1'26 and $0.51 in Q2'25 Non-GAAP gross margin of 6.4% versus 11.9% in Q2'25 Non-GAAP diluted net

    2/3/26 4:51:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    Supermicro to Report Second Quarter Fiscal 2026 Financial Results on February 3rd, 2026

    Super Micro Computer, Inc. (SMCI), a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and 5G/Edge, today announced that it will host its second quarter fiscal 2026 financial results conference call on Tuesday, February 3rd, 2026, at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be available at https://ir.supermicro.com. A replay of the webcast will be available shortly after the call at the same website and will remain accessible for one year. About Super Micro Computer, Inc. Supermicro (NASDAQ:SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation

    1/22/26 4:31:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology